Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyCarboxymethylcellulose
Identification
- Name
- Carboxymethylcellulose
- Accession Number
- DB11059
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Description
Carboxymethylcellulose is a cellulose derivative that consists of the cellulose backbone made up of glucopyranose monomers and their hydroxyl groups bound to carboxymethyl groups. It is added in food products as a viscosity modifier or thickener and emulsifier. It is also one of the most common viscous polymers used in artificial tears, and has shown to be effective in the treatment of aqueous tear-deficient dry eye symptoms and ocular surface staining [1]. The viscous and mucoadhesive properties as well as its anionic charge allow prolonged retention time in the ocular surface [1]. Sodium carboxymethylcellulose is the most commonly used salt.
- Synonyms
- Carbose
- Carboxymethyl cellulose
- Carmellose
- Cellulose carboxymethyl ether
- Cellulose gum
- Cellulose, carboxymethyl ether
- Thylose
- Product Ingredients
Ingredient UNII CAS InChI Key Carboxymethylcellulose sodium K679OBS311 9004-32-4 Not applicable - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Artificial Tears Solution / drops 10 mg/1mL Ophthalmic Aru Pharma Inc. 2018-01-22 Not applicable US 
Biolle Gel Tears Solution / drops 10 mg/1mL Ophthalmic Sage Ethnographic Research, Dba Biollé 2015-06-01 Not applicable US Biolle Tears Solution / drops 5 mg/1mL Ophthalmic Sage Ethnographic Research, Dba Biollé 2015-06-01 Not applicable US Carboxymethylcellulose sodium Solution 5 mg/1mL Ophthalmic Promed Exports Private Limited 2009-10-01 Not applicable US CareOne Lubricant Solution / drops 5 mg/1mL Ophthalmic Foodhold U.S.A. 2017-05-18 Not applicable US CareOne Lubricant Eye Plus Solution / drops 0.5 g/100mL Ophthalmic American Sales Company 2013-06-20 Not applicable US Cellufresh Liq 0.5% Liquid 0.5 % Ophthalmic Allergan 1992-12-31 2000-06-01 Canada 
CMC Lubricant Eye Drops Solution / drops 5 mg/1mL Ophthalmic Amerisource Bergen 2013-03-22 Not applicable US CVS Lubricant Eye Solution / drops 2.5 mg/1mL Ophthalmic CVS Health 2016-03-04 Not applicable US Equate Restore Plus Lubricant Eye Solution / drops 5 mg/1mL Ophthalmic Walmart Stores 2013-09-05 Not applicable US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Clear Eyes for Dry Eyes Carboxymethylcellulose sodium (1.0 %) + Glycerin (0.25 %) Solution Ophthalmic Prestige Brands Inc 2008-03-26 2014-03-20 Canada CVS Moisturizing Lubricating Eye Carboxymethylcellulose sodium (5 mg/100mg) + Glycerin (9 mg/100mg) Solution / drops Ophthalmic CVS Health 2013-09-03 Not applicable US CVS Moisturizing Lubricating Eye Twin Pack Carboxymethylcellulose sodium (5 mg/1mL) + Glycerin (9 mg/1mL) Solution / drops Ophthalmic CVS Health 2014-07-10 Not applicable US Equate Comfort Carboxymethylcellulose sodium (2.5 mg/1mL) + Hypromellose (3 mg/1mL) Gel Ophthalmic Walmart Stores 2014-04-10 Not applicable US Equate Day and Night Restore Tears Carboxymethylcellulose sodium (5 mg/1mL) + Mineral oil (425 mg/1g) + Petrolatum (573 mg/1g) Kit Walmart Stores 2018-06-01 Not applicable US Equate Lubricating Eye Carboxymethylcellulose sodium (5 mg/1mL) + Glycerin (9 mg/1mL) Solution / drops Ophthalmic Walmart Stores 2012-04-01 Not applicable US Equate Restore Dual Lubricating Carboxymethylcellulose sodium (5 mg/1mL) + Glycerin (9 mg/1mL) Solution / drops Ophthalmic Walmart 2018-03-01 Not applicable US Equate Restore Dual Sensitive Lubricant Carboxymethylcellulose sodium (5 mg/1mL) + Glycerin (9 mg/1mL) Solution / drops Ophthalmic Walmart Stores 2016-05-03 Not applicable US Genteal Geldrops Carboxymethylcellulose sodium (0.25 %) + Hypromellose (0.3 %) Solution Ophthalmic Alcon, Inc. 2007-01-03 2014-01-13 Canada GenTeal Moderate to Severe Carboxymethylcellulose sodium (2.5 mg/1mL) + Hypromellose (3 mg/1mL) Gel Ophthalmic Novartis 2009-09-14 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Acne Pimple Master Patch Carboxymethylcellulose sodium (30 mg/10g) Patch Topical Cosrx Inc. 2015-12-28 2015-12-31 US Cho-A Derm Carboxymethylcellulose sodium (130 g/433g) Dressing Topical Cho-A Pharm.Co.,Ltd. 2018-06-19 Not applicable US Mizon Bye Bye Pimple Carboxymethylcellulose (1.05 g/3.5g) Patch Topical Mizon Co.,Ltd. 2018-05-01 Not applicable US Trouble Clear Spot Carboxymethylcellulose sodium (36.87 mg/241) Patch Topical Skinfood Co., Ltd. 2016-04-01 2017-03-01 US Trouble Clear Spot 0.7cm Carboxymethylcellulose sodium (6.17 mg/101) Patch Topical Skinfood Co., Ltd. 2015-02-01 2017-03-01 US Trouble Clear Spot 1.0cm Carboxymethylcellulose sodium (12.58 mg/51) Patch Topical Skinfood Co., Ltd. 2015-02-01 2017-03-01 US Trouble Clear Spot 1.2cm Carboxymethylcellulose sodium (18.12 mg/91) Patch Topical Skinfood Co., Ltd. 2015-02-01 2017-03-01 US - Categories
- UNII
- 05JZI7B19X
- CAS number
- 9000-11-7
- Weight
- Not Available
- Chemical Formula
- Not Available
- InChI Key
- Not Available
- InChI
- Not Available
- IUPAC Name
- Not Available
- SMILES
- Not Available
Pharmacology
- Indication
Indicated for the symptomatic relief of burning, irritation and discomfort of the eyes due to dryness or exposure to wind or sun.
- Pharmacodynamics
In a randomized clinical study of patients with mild or moderate forms of eye dryness, ophthalmic treatment with sodium carboxymethylcellulose resulted in a diminished frequency of symptoms compared to the placebo group [2]. Carboxymethylcellulose interacts with human corneal epithelial cells to facilitate corneal epithelial wound healing and attenuate eye irritation in a dose-dependent manner [1]. It exhibits protective actions on the ocular surface in various applications; it mediates cytoprotective effects on the ocular surface when applied prior to contact lenses and reduces the incidence of epithelial defects during LASIK [1].
- Mechanism of action
Carboxymethylcellulose binds to the surface of corneal epithelial cells via its glucopyranose subunits binding to glucose receptors GLUT-1 [1]. The residence time of carboxymethylcellulose bound to corneal cells is approximately 2 hours as indicated by a short-term binding assay [1]. Binding of carboxymethylcellulose to the matrix proteins stimulated corneal epithelial cell attachment, migration, and re-epithelialization of corneal wounds [1].
Target Actions Organism USolute carrier family 2, facilitated glucose transporter member 1 binderHuman - Absorption
No pharmacokinetic data available.
- Volume of distribution
No pharmacokinetic data available.
- Protein binding
No pharmacokinetic data available.
- Metabolism
No pharmacokinetic data available.
- Route of elimination
No pharmacokinetic data available.
- Half life
No pharmacokinetic data available.
- Clearance
No pharmacokinetic data available.
- Toxicity
Rat oral LD50, rabbit dermal LD50, and rat inhalation LC50 of sodium carboxymethyl cellulose are 27000 mg/kg, >2 g/kg, and >5800 mg/m^3 (4 hours), respectively [MSDS].
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group Agmatine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Agmatine. Experimental, Investigational Aluminum hydroxide The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Aluminum hydroxide. Approved, Investigational Amiloride The risk or severity of adverse effects can be increased when Amiloride is combined with Carboxymethylcellulose. Approved Amiodarone The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Amiodarone. Approved, Investigational Amlodipine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Amlodipine. Approved Aranidipine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Aranidipine. Approved, Investigational Atropine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Atropine. Approved, Vet Approved Azelnidipine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Azelnidipine. Approved, Investigational Barnidipine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Barnidipine. Approved Bencyclane The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Bencyclane. Experimental Benidipine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Benidipine. Approved, Investigational Benzatropine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Benzatropine. Approved Bepridil The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Bepridil. Approved, Withdrawn Bioallethrin The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Bioallethrin. Approved, Experimental Brompheniramine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Brompheniramine. Approved Bumetanide The risk or severity of adverse effects can be increased when Bumetanide is combined with Carboxymethylcellulose. Approved Calcium Carbonate The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Calcium Carbonate. Approved, Investigational Carboxyamidotriazole The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Carboxyamidotriazole. Investigational Caroverine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Caroverine. Experimental Chlorpromazine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Chlorpromazine. Approved, Investigational, Vet Approved Cilnidipine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Cilnidipine. Approved, Investigational Cinnarizine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Cinnarizine. Approved, Investigational Clevidipine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Clevidipine. Approved, Investigational Codeine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Codeine. Approved, Illicit Cyclandelate The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Cyclandelate. Approved Dapagliflozin The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Carboxymethylcellulose. Approved Darodipine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Darodipine. Experimental Dexniguldipine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Dexniguldipine. Experimental Dexverapamil The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Dexverapamil. Experimental Diltiazem The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Diltiazem. Approved, Investigational Diphenhydramine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Diphenhydramine. Approved, Investigational Dotarizine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Dotarizine. Investigational Doxepin The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Doxepin. Approved, Investigational Doxylamine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Doxylamine. Approved, Vet Approved Efonidipine The risk or severity of adverse effects can be increased when Efonidipine is combined with Carboxymethylcellulose. Approved, Investigational Emopamil The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Emopamil. Experimental Eperisone The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Eperisone. Approved, Investigational Ethopropazine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Ethopropazine. Approved Ethosuximide The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Ethosuximide. Approved Felodipine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Felodipine. Approved, Investigational Fendiline The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Fendiline. Withdrawn Fentanyl The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Fentanyl. Approved, Illicit, Investigational, Vet Approved Fish oil The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Fish oil. Approved, Nutraceutical Flunarizine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Flunarizine. Approved Fluoxetine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Fluoxetine. Approved, Vet Approved Fluspirilene The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Fluspirilene. Approved, Investigational Furosemide The risk or severity of adverse effects can be increased when Furosemide is combined with Carboxymethylcellulose. Approved, Vet Approved Gabapentin The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Gabapentin. Approved, Investigational Gallopamil The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Gallopamil. Investigational Hydrochlorothiazide The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Carboxymethylcellulose. Approved, Vet Approved Hydrocodone The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Hydrocodone. Approved, Illicit, Investigational Hydromorphone The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Hydromorphone. Approved, Illicit Hyoscyamine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Hyoscyamine. Approved Imipramine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Imipramine. Approved Ipratropium The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Ipratropium. Approved Isoflurane The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Isoflurane. Approved, Vet Approved Isradipine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Isradipine. Approved, Investigational Lacidipine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Lacidipine. Approved, Investigational Lamotrigine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Lamotrigine. Approved, Investigational Lercanidipine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Lercanidipine. Approved, Investigational Levetiracetam The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Levetiracetam. Approved, Investigational Lidoflazine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Lidoflazine. Experimental Lomerizine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Lomerizine. Experimental Loperamide The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Loperamide. Approved Magnesium sulfate The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Magnesium sulfate. Approved, Investigational, Vet Approved Manidipine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Manidipine. Approved, Investigational Mannitol The risk or severity of adverse effects can be increased when Mannitol is combined with Carboxymethylcellulose. Approved, Investigational Menthol The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Menthol. Approved Methotrimeprazine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Methotrimeprazine. Approved, Investigational Methsuximide The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Methsuximide. Approved Metolazone The risk or severity of adverse effects can be increased when Metolazone is combined with Carboxymethylcellulose. Approved Mibefradil The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Mibefradil. Investigational, Withdrawn Morphine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Morphine. Approved, Investigational Naftopidil The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Naftopidil. Investigational Nalbuphine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Nalbuphine. Approved Nicardipine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Nicardipine. Approved, Investigational Nifedipine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Nifedipine. Approved Niguldipine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Niguldipine. Experimental Niludipine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Niludipine. Experimental Nilvadipine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Nilvadipine. Approved, Investigational Nimesulide The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Nimesulide. Approved, Investigational, Withdrawn Nimodipine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Nimodipine. Approved, Investigational Nisoldipine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Nisoldipine. Approved Nitrendipine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Nitrendipine. Approved, Investigational Nortriptyline The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Nortriptyline. Approved Nylidrin The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Nylidrin. Approved Orphenadrine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Orphenadrine. Approved Otilonium The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Otilonium. Experimental, Investigational Oxycodone The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Oxycodone. Approved, Illicit, Investigational Oxymorphone The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Oxymorphone. Approved, Investigational, Vet Approved Paroxetine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Paroxetine. Approved, Investigational Penfluridol The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Penfluridol. Experimental Pinaverium The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Pinaverium. Approved Prenylamine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Prenylamine. Withdrawn Promethazine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Promethazine. Approved, Investigational Quetiapine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Quetiapine. Approved Scopolamine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Scopolamine. Approved, Investigational Seletracetam The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Seletracetam. Investigational Spironolactone The risk or severity of adverse effects can be increased when Spironolactone is combined with Carboxymethylcellulose. Approved Terodiline The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Terodiline. Experimental Tetrahydropalmatine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Tetrahydropalmatine. Investigational Tetrandrine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Tetrandrine. Experimental Tolfenamic Acid The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Tolfenamic Acid. Approved, Investigational Tramadol The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Tramadol. Approved, Investigational Tranilast The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Tranilast. Approved, Investigational Trimebutine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Trimebutine. Approved Trimethadione The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Trimethadione. Approved Trospium The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Trospium. Approved Verapamil The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Verapamil. Approved Vinpocetine The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Vinpocetine. Investigational WIN 55212-2 The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with WIN 55212-2. Experimental Ziconotide The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Ziconotide. Approved Zonisamide The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Zonisamide. Approved, Investigational - Food Interactions
- Not Available
References
- General References
- Garrett Q, Simmons PA, Xu S, Vehige J, Zhao Z, Ehrmann K, Willcox M: Carboxymethylcellulose binds to human corneal epithelial cells and is a modulator of corneal epithelial wound healing. Invest Ophthalmol Vis Sci. 2007 Apr;48(4):1559-67. doi: 10.1167/iovs.06-0848. [PubMed:17389485]
- Bruix A, Adan A, Casaroli-Marano RP: [Efficacy of sodium carboxymethylcellulose in the treatment of dry eye syndrome]. Arch Soc Esp Oftalmol. 2006 Feb;81(2):85-92. [PubMed:16511715]
- External Links
- PubChem Substance
- 347911098
- ChEMBL
- CHEMBL1909054
- Wikipedia
- Carboxymethylcellulose
- AHFS Codes
- 28:20.00 — Anorexigenic Agents & Respiratory and CNS Stimulants
- 52:13.00* — Artificial Tears
- 52:92.00 — EENT Drugs, Miscellaneous
- MSDS
- Download (34 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
Form Route Strength Patch Topical 30 mg/10g Solution / drops Ophthalmic 10 mg/1mL Solution Ophthalmic 5 mg/1mL Liquid Ophthalmic 0.5 % Dressing Topical 130 g/433g Solution / drops Ophthalmic Kit Liquid Intraocular 5 mg/1mL Solution Ophthalmic Gel Ophthalmic Solution, gel forming / drops Ophthalmic 0.5 g/100mL Solution / drops Ophthalmic 0.5 g/100mL Solution, gel forming / drops Ophthalmic .5 g/100mL Solution / drops Ophthalmic .5 g/100mL Patch Topical 1.05 g/3.5g Capsule Oral 300 mg Paste Oral; Topical Solution / drops Ophthalmic 0.25 % Solution / drops Ophthalmic 1 % Solution Ophthalmic 0.5 % Solution Ophthalmic 10 mg Emulsion Ophthalmic Solution / drops Ophthalmic 5 mg Solution / drops Ophthalmic 0.5 % Solution / drops Ophthalmic 5 mg/1mL Kit; solution Ophthalmic Aerosol Oral Gel Ophthalmic 10 mg/1mL Solution / drops Ophthalmic 2.5 mg/1mL Solution Ophthalmic 0.25 % Patch Topical 36.87 mg/241 Patch Topical 6.17 mg/101 Patch Topical 12.58 mg/51 Patch Topical 18.12 mg/91 - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 300 MSDS - Predicted Properties
- Not Available
- Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Taxonomy
- Classification
- Not classified
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Binder
- General Function
- Xenobiotic transporter activity
- Specific Function
- Facilitative glucose transporter. This isoform may be responsible for constitutive or basal glucose uptake. Has a very broad substrate specificity; can transport a wide range of aldoses including b...
- Gene Name
- SLC2A1
- Uniprot ID
- P11166
- Uniprot Name
- Solute carrier family 2, facilitated glucose transporter member 1
- Molecular Weight
- 54083.325 Da
References
- Garrett Q, Simmons PA, Xu S, Vehige J, Zhao Z, Ehrmann K, Willcox M: Carboxymethylcellulose binds to human corneal epithelial cells and is a modulator of corneal epithelial wound healing. Invest Ophthalmol Vis Sci. 2007 Apr;48(4):1559-67. doi: 10.1167/iovs.06-0848. [PubMed:17389485]
Drug created on December 03, 2015 09:51 / Updated on September 17, 2018 21:03